GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

Inicio・Lista de Acciones・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Abierto

283.7 4.34

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

273.2

Máximo

284.15

Métricas clave
By Trading Economics
Ingresos	22B 49B
Ventas	18B 97B
P/B Media del Sector	10.261 49.888
BPA	10.91
Rentabilidad por dividendo	4.11
Margen de beneficios	50.15
Empleados	67,900
EBITDA	32B 69B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+9.53% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	4.11% 2.38%
Próximas Ganancias	5 ago 2026
Próxima Fecha de Ex Dividendo	13 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-8.3B 1.2T
Apertura anterior	279.36
Cierre anterior	283.7

Novo Nordisk A-S (Class B) Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 may 2026, 15:48 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6 may 2026, 07:30 UTC

Ganancias

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 may 2026, 06:19 UTC

Ganancias

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

3 jun 2026, 09:48 UTC

Charlas de Mercado

Novo Nordisk's UAE Wegovy Pill Launch an Important Step -- Market Talk

29 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

18 may 2026, 13:10 UTC

Charlas de Mercado

Ganancias

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12 may 2026, 12:05 UTC

Acciones populares

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 may 2026, 10:51 UTC

Acciones populares

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 may 2026, 09:42 UTC

Ganancias

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12 may 2026, 09:08 UTC

Acciones populares

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11 may 2026, 20:30 UTC

Ganancias

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7 may 2026, 09:30 UTC

Ganancias

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 may 2026, 12:36 UTC

Ganancias

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 may 2026, 10:53 UTC

Acciones populares

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 may 2026, 10:12 UTC

Ganancias

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 may 2026, 09:58 UTC

Ganancias

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 may 2026, 09:35 UTC

Acciones populares

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 may 2026, 08:13 UTC

Charlas de Mercado

Ganancias

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 may 2026, 07:43 UTC

Charlas de Mercado

Ganancias

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 may 2026, 07:00 UTC

Ganancias

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 may 2026, 06:34 UTC

Ganancias

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 may 2026, 06:26 UTC

Ganancias

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 may 2026, 06:26 UTC

Ganancias

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 may 2026, 06:24 UTC

Ganancias

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 may 2026, 06:20 UTC

Ganancias

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 may 2026, 06:19 UTC

Ganancias

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 may 2026, 06:13 UTC

Ganancias

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 may 2026, 06:13 UTC

Ganancias

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 may 2026, 06:12 UTC

Ganancias

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 may 2026, 05:43 UTC

Ganancias

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S (Class B) previsión

Precio Objetivo

By TipRanks

9.53% repunte

Estimación a 12 Meses

Media 1,162.73 DKK 9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.